|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intranasal rapamycin ameliorates Alzheimerlike cognitive decline in a mouse model of Down syndrome显示文摘Background:Down syndrome(DS)individuals,by the age of 40s,are at increased risk to develop Alzheimer-like dementia,with deposition in brain of senile plaques and neurofibrillary tangles.Our laboratory recently demonstrated the disturbance of PI3K/AKT/mTOR axis in DS brain,prior and after the development of Alzheimer Disease(AD).The aberrant modulation of the mTOR signalling in DS and AD age-related cognitive decline affects crucial neuronal pathways,including insulin signaling and autophagy,involved in pathology onset and progression.Within this context,the therapeutic use of mTOR-inhibitors may prevent/attenuate the neurodegenerative phenomena.By our work we aimed to rescue mTOR signalling in DS mice by a novel rapamycin intranasal administration protocol(InRapa)that maximizes brain delivery and reduce systemic side effects.Methods:Ts65Dn mice were administered with InRapa for 12 weeks,starting at 6 months of age demonstrating,at the end of the treatment by radial arms maze and novel object recognition testing,rescued cognition.Results:The analysis of mTOR signalling,after InRapa,demonstrated in Ts65Dn mice hippocampus the inhibition of mTOR(reduced to physiological levels),which led,through the rescue of autophagy and insulin signalling,to reduced APP levels,APP processing and APP metabolites production,as well as,to reduced tau hyperphosphorylation.In addition,a reduction of oxidative stress markers was also observed.Discussion:These findings demonstrate that chronic InRapa administration is able to exert a neuroprotective effect on Ts65Dn hippocampus by reducing AD pathological hallmarks and by restoring protein homeostasis,thus ultimately resulting in improved cognition.Results are discussed in term of a potential novel targeted therapeutic approach to reduce cognitive decline and AD-like neuropathology in DS individuals. | Antonella Tramutola Chiara Lanzillotta Eugenio Barone Andrea Arena Ilaria Zuliani Luciana Mosca Carla Blarzino D.Allan Butterfield Marzia Perluigi Fabio Di Domenico | 2018 | Translational Neurodegeneration2018，7，1： | 3 |
| 2 | Novel frontiers of agents for bowel cleansing for colonoscopy显示文摘The incidence of colorectal cancer(CRC)is characterized by rapid declines in the wake of widespread screening.Colonoscopy is the gold standard for CRC screening,but its accuracy is related to high quality of bowel preparation(BP).In this review,we aimed to summarized the current strategy to increase bowel cleansing before colonoscopy.Newly bowel cleansing agents were developed with the same efficacy of previous agent but requiring less amount of liquid to improve patients’acceptability.The role of the diet before colonoscopy was also changed,as well the contribution of educational intervention and the use of adjunctive drugs to improve patients’tolerance and/or quality of BP.The review also described BP in special situations,as lower gastrointestinal bleeding,elderly people,patients with chronic kidney disease,patients with inflammatory bowel disease,patients with congestive heart failure,inpatient,patient with previous bowel resection,pregnant/lactating patients.The review underlined the quality of BP should be described using a validate scale in colonoscopy report and it explored the available scales.Finally,the review explored the possible contribution of bowel cleansing in post-colonoscopy syndrome that can be related by a transient alteration of gut microbiota.Moreover,the study underlined several points needed to further investigations. | Milena Di Leo Andrea Iannone Monica Arena Giuseppe Losurdo Maria Angela Palamara Giuseppe Iabichino Pierluigi Consolo Maria Rendina Carmelo Luigiano Alfredo Di Leo | 2021 | World Journal of Gastroenterology2021，27，45： | 2 |
| 3 | Anti-tumor necrosis factor α therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis显示文摘BACKGROUND Anti-tumor necrosis factor α(TNFα) represents the best therapeutic option to induce mucosal healing and clinical remission in patients with moderate-severe ulcerative colitis. On the other side gut microbiota plays a crucial role in pathogenesis of ulcerative colitis but few information exists on how microbiota changes following anti-TNFα therapy and on microbiota role in mucosal healing.AIM To elucidate whether gut microbiota and immune system changes appear following anti TNFα therapy during dextran sulfate sodium(DSS) colitis.METHODS Eighty C57 BL/6 mice were divided into four groups: 'No DSS', 'No DSS + antiTNFα', 'DSS' and 'DSS + anti-TNFα'. 'DSS' and 'DSS + anti-TNFα' were treated for 5 d with 3% DSS. At day 3, mice whithin 'No DSS+anti-TNFα' and'DSS+anti-TNFα' group received 5 mg/kg of an anti-TNFα agent. Forty mice were sacrificed at day 5, forty at day 12, after one week of recovery post DSS. The severity of colitis was assessed by a clinical score(Disease Activity Index), colon length and histology. Bacteria such as Bacteroides, Clostridiaceae, Enterococcaceae and Fecalibacterium prausnitzii(F. prausnitzii) were evaluated by quantitative PCR.Type 1 helper T lymphocytes(Th1), type 17 helper T lymphocytes(Th17) and CD4+ regulatory T lymphocytes(Treg) distributions in the mesenteric lymph node(MLN) were studied by flow cytometry.RESULTS Bacteria associated with a healthy state(i.e., such as Bacteroides, Clostridiaceae and F. prausnitzii) decreased during colitis and increased in course of anti-TNFαtreatment. Conversely, microorganisms belonging to Enterococcaceae genera,which are linked to inflammatory processes, showed an opposite trend.Furthermore, in colitic mice treated with anti-TNFα microbial changes were associated with an initial increase(day 5 of the colitis) in Treg cells and a consequent decrease(day 12 post DSS) in Th1 and Th17 frequency cells. Healthy mice treated with anti-TNFα showed the same histological, microbial and immune features of untreated colitic mice. 'No DSS + anti-TNFα' group showed a lymphomononuclear infiltrate both at 5 th and 12 th d at hematoxylin and eosin staining, an increase of in Th1 and Th17 frequency at day 12, an increase of Enterococcaceae at day 5, a decrease of Bacteroides and Clostridiaceae at day 12.CONCLUSION Anti-TNFα treatment in experimental model of colitis improves disease activity but it is associated to an increase in Th17 pathway together with gut microbiota alteration. | Valentina Petito Cristina Graziani Loris R Lopetuso Marco Fossati Alessandra Battaglia Vincenzo Arena Domenico Scannone Gianluca Quaranta Andrea Quagliariello Federica Del Chierico Lorenza Putignani Luca Masucci Maurizio Sanguinetti Alessandro Sgambato Antonio Gasbarrini Franco Scaldaferri | 2019 | World Journal of Gastroenterology2019，25，12： | 2 |
| 4 | Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis显示文摘 | Andrea Lisotti Francesco Azzaroli Federica Buonfiglioli Marco Montagnani Paolo Cecinato Laura Turco Claudio Calvanese Patrizia Simoni Massimo Guardigli Rosario Arena Alessandro Cucchetti Antonio Colecchia Davide Festi Rita Golfieri Giuseppe Mazzella | 2014 | Hepatology2014，，2： | 2 |
| 5 | Severe immune thrombocytopenia after peg-interferonalpha2a, ribavirin and telaprevir treatment completion: a case report and systematic review of literature显示文摘Mild to moderate autoimmune thrombocytopenia(AITP) is a common finding in patients receiving interferonbased antiviral treatment, due to bone marrow suppression. Here we report the case of a patient with chronic genotype 1b hepatitis C virus(HCV) infection treated with pegylated-interferon alpha-2a, ribavirin and telaprevir for 24 wk; the patient developed severe AITP three weeks after treatment withdrawal. We performed a systematic literature search in order to review all published cases of AITP related to HCV antiviral treatment. To our knowledge, this is the second case of AITP observed after antiviral treatment withdrawal. In most published cases AITP occurred during treatment; in fact, among 24 cases of AITP related to interferonbased antiviral treatment, only one occurred after discontinuation. Early diagnosis of AITP is a key factor in order to achieve an early interferon discontinuation; in the era of new direct antiviral agents those patients have to be considered for interferon-free treatment regimens. Prompt prescription of immuno-suppressant treatment(i.e., corticosteroids, immunoglobulin infusion and even rituximab for unresponsive cases) leads to favourable prognosis in most of cases. Physicians using interferonbased treatments should be aware that AITP can occur both during and after treatment, specially in the new era of interferon-free antiviral treatment. Finally, in the case of suspected AITP, presence of anti-platelet antibodies should be checked not only during treatment but alsoafter discontinuation. | Rosario Arena Paolo Cecinato Andrea Lisotti Federica Buonfiglioli Claudio Calvanese Giuseppe Grande Marco Montagnani Francesco Azzaroli Giuseppe Mazzella | 2015 | World Journal of Hepatology2015，7，12： | 2 |
| 6 | CTX-M-type be- ta-lactamases: A successful story of antibiotic resistance 显示文摘 | D'Andrea M M Arena F Pallecchi L | 2013 | In- tern J Med Microbiol2013，303，67： | 1 |
| 7 | CTX-M-type beta-lactamases:a successful story of antibiotic resistance显示文摘 | D'Andrea MM Arena F Pallecchi L | 2013 | Int J Med Microbiol2013，303，67： | 1 |
| 8 | CTX-M-typeβ-lactamases:Asuccessful story of antibiot- ic resistance显示文摘 | Marco Maria D'Andrea Fabio Arena Lucia Pallecchi Gian Maria Rossolini | 2013 | Int J Med Microbiol2013，8，4： | 1 |
| 9 | CTX-M-type 13-lacta- mases: a successful story of antibiotic resistance显示文摘 | D'andrea M M Arena F Pallecchi L | 2013 | Int J Med Micro- biol2013，303，67： | 1 |
| 10 | CTX-M-type be- ta-lactamases: a successful story of antibiotic resistance 显示文摘 | D'Andrea MM Arena F Pallecchi L | 2013 | Int J Med Microbiol2013，18，2： | 1 |
| 11 | The expression of tomato prosystemin gene in tobacco plants highly affects host proteomic repertoire显示文摘 | Mariapina Rocco Giandomenico Corrado Simona Arena Chiara D’Ambrosio Claudia Tortiglione Stefano Sellaroli Mauro Marra Rosa Rao Andrea Scaloni | 2008 | Journal of Proteomics2008，，2： | 1 |
| 12 | Surgical Management of Abdominal Manifestations of Type 1 Neurofibromatosis: Experience of a Single Center显示文摘 | Cavallaro Giuseppe Basile Ursula Polistena Andrea Giustini Sandra Arena Rossella Scorsi Alessandro Zinnamosca Laura Letizia Claudio Calvieri Stefano De Toma Giorgio | 2010 | The American Surgeon2010，，4： | 1 |
| 13 | Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases显示文摘AIM:To assess clinical and endoscopic response to propionyl-L-carnitine hydrochloride(PLC) in colonic inflammatory bowel disease.METHODS:Patients suffering from mild to moderate ulcerative colitis(UC) or Crohn's disease(CD) colitis,with disease activity index(DAI) between 3 and 10 and under stable therapy with oral aminosalicylates,mercaptopurine or azathioprine,for at least 8 wk prior to baseline assessments,were considered suitable for enrollment.Fourteen patients were enrolled to assume PLC 2 g/d(two active tablets twice daily) orally.Clinical-endoscopic and histological activity were assessed by DAI and histological index(HI),respectively,following a colonoscopy performed immediately before and after 4 wk treatment.Clinical response was defined as a lowering of at least 3 points in DAI and clinical remission as a DAI score ≤ 2.Histological response was defined as an improvement of HI of at least 1 point.We used median values for the analysis.Differences pre-and post-treatment were analyzed by Wilcoxon signed rank test.RESULTS:All patients enrolled completed the study.One patient,despite medical advice,took deflazacort 5 d before follow-up colonoscopy examination.No side effects were reported by patients during the trial.After treatment,71%(SE 12%) of patients achieved clinical response,while 64%(SE 13%) obtained remission.Separating UC from CD patients,we observed a clinical response in 60%(SE 16%) and 100%,respectively.Furthermore 60%(SE 16%) of UC patients and 75%(SE 25%) of CD patients were in clinical remission after therapy.The median DAI was 7 [interquartile range(IQR):4-8] before treatment and decreased to 2(IQR:1-3)(P < 0.01) after treatment.Only patients with UC showed a significant reduction of DAI,from a median 6.5(IQR:4-9) before treatment to 2(IQR:1-3) after treatment(P < 0.01).Conversely,in CD patients,although displaying a clear reduction of DAI from 7(IQR:5.5-7.5) before therapy to 1.5(IQR:0.5-2.5) after therapy,differences observed were not significant(P = 0.06).Seventy-nine percent(SE 11%) of patients showed improvement of HI of at least 1 point,while only one CD and two UC patients showed HI stability;none showed HI worsening.Median HI decreased from 1(IQR:1-2),to 0.5(IQR:0-1) at the endoscopic control in the whole population(P < 0.01),while it changed from 1(IQR:1-2) to 0.5(IQR:0-1) in UC patients(P < 0.01) and from 1.5(IQR:1-2) to 0.5(IQR:0-1) in CD patients(P = not significant).The two sample tests of proportions showed no significant differences in clinical and histological response or in clinical remission between UC and CD patients.No side effects were reported during treatment or at 4 wk follow-up visit.CONCLUSION:PLC improves endoscopic and histological activity of mild to moderate UC.Further studies are required to evaluate PLC efficacy in colonic CD patients. | Giuseppe Merra Giovanni Gasbarrini Lucrezia Laterza Marco Pizzoferrato Andrea Poscia Franco Scaldaferri Vincenzo Arena Francesca Fiore Achille Cittadini Alessandro Sgambato Francesco Franceschi Antonio Gasbarrini | 2012 | World Journal of Gastroenterology2012，18，36： | 1 |
| 14 | Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)显示文摘 | Antonio Abbate Michael C. Kontos John D. Grizzard Giuseppe G.L. Biondi-Zoccai Benjamin W. Van Tassell Roshanak Robati Lenore M. Roach Ross A. Arena Charlotte S. Roberts Amit Varma Christopher C. Gelwix Fadi N. Salloum Andrea Hastillo Charles A. Dinarello | 2010 | The American Journal of Cardiology2010，，10： | 1 |
| 15 | Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)显示文摘 | Antonio Abbate Michael C. Kontos John D. Grizzard Giuseppe G.L. Biondi-Zoccai Benjamin W. Van Tassell Roshanak Robati Lenore M. Roach Ross A. Arena Charlotte S. Roberts Amit Varma Christopher C. Gelwix Fadi N. Salloum Andrea Hastillo Charles A. Dinarello | 2010 | The American Journal of Cardiology2010，，10： | 1 |
| 16 | CTX M type beta-lactamases A successful story of antibiotic resistance显示文摘 | D'Andrea M M Arena F Pallecchi L | 2013 | International Journal of Medical Mi crobiology2013，303，67： | 1 |
| 17 | Flutter of an arch bridge via a fully nonlinear continuum formulation显示文摘 | Walter Lacarbonara Andrea Arena | 2011 | Journal of Aerospace Engineering2011，24，1： | 1 |
| 18 | CTX-M-Type β- lactamases: a successful story of antibiotic resistance 显示文摘 | D'Andrea MM Arena F Palleechi L | 2013 | Int J Med Microbiol2013，303，67： | 1 |
| 19 | Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib显示文摘AIM:To investigate in greater detail the efficacy and safety of sorafenib for the treatment of hepatocellular carcinoma(HCC)in patients with established cirrhosis.METHODS:From October 2009 to July 2012 patients with an established diagnosis of cirrhosis and HCC treated with sorafenib were consecutively enrolled.According to the Barcelona Clinic Liver Cancer(BCLC)classification,patients were in the advanced stage(BCLC-C)or in the intermediate stage(BCLC-B)but unfit or unresponsive to other therapeutic strategies.Treatment was evaluated performing a 4-phase computed tomography or magnetic resonance imaging scan every 2-3 mo,and analyzed according to the modified Response Evaluation Criteria in Solid Tumors.Sorafenib was administered at 800 mg/d,until radiological progression or occurrence of unacceptable adverse events(AEs).Univariate and multivariate analyses identified predictors of 16-wk clinical benefit and overall survival.RESULTS:Forty-four patients were enrolled,15 had intermediate HCC and 14 a Child-Pugh score of B7.AEs caused treatment interruption in 19 patients(43%),and median treatment duration was shorter in this subset(5 wk vs 19 wk,P<0.001)and in the BCLC-C subgroup(13 wk vs 40 wk,P=0.015).No significant differences in the reason for treatment interruption or in treatment duration were found comparing patients in Child-Pugh class A vs B or in patients older or younger than 70 years.After 16 wk of treatment,18 patients(41%)had stable disease or partial response.Patients with viral infection or BCLC-C were at higher risk of disease progression.ECOG,extrahepatic spread,macrovascular invasion,alpha-fetoprotein or alkaline phosphatase levels at admission were independent predictors of overall survival.CONCLUSION:In patients with cirrhosis and HCC treated with sorafenib,AEs are a common cause of early treatment withdrawal.Vascular invasion and extrahepatic spread condition early response to treatment and survival.Baseline biochemical parameters may be helpful to identify patients at higher risk of shorter overall survival. | Andrea L Inghilesi Donatella Gallori Lorenzo Antonuzzo Paolo Forte Daniela Tomcikova Umberto Arena Stefano Colagrande Silvia Pradella Bernardo Fani Elena Gianni Luca Boni Giacomo Laffi Francesco Di Costanzo Fabio Marra | 2014 | World Journal of Gastroenterology2014，20，3： | 1 |
| 20 | CTX-M type -laetamases:a successful story of antibiotic re- sistance显示文摘 | D'Andrea MM Arena F Pallecchi L | 2013 | Int J Med Microbiol2013，303，67： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员